INFINITY PHARMACEUTICALS, INC.
DelistedCIK 1113148fmd_00GH0PJMQGHQ92QRYFQAENHV62Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Jun 30, 2023, 54 periods
| Line item | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | 6 | 22 | 3 | 2 | 2 | 3 |
| Research and development | 100 | 144 | 199 | 120 | 21 | 20 | 27 | 27 | 32 | 32 |
| Total operating expenses | 128 | 173 | 236 | 162 | 42 | 34 | 49 | 40 | 47 | 47 |
| Operating income | (128) | (8) | (127) | (31) | (36) | (12) | (46) | (38) | (45) | (45) |
| Interest expense | – | 10 | 1 | 1 | 1 | 0 | 3 | – | – | – |
| Interest and investment income | – | – | – | – | – | – | – | – | – | – |
| Other non-operating income (expense) | 1 | (9) | (1) | 1 | (6) | 1 | (1) | (2) | (0) | 0 |
| Income before taxes | (127) | (17) | (128) | (30) | (43) | (11) | (47) | (40) | – | – |
| Income tax expense | 0 | 0 | 0 | 0 | (1) | 0 | (0) | 0 | 0 | 0 |
| Net income from continuing operations | (127) | (17) | (128) | (30) | (42) | (11) | (47) | (40) | – | – |
| Net income | (127) | (17) | (128) | (30) | (42) | (11) | (47) | (40) | (45) | (44) |